Lampgen Clinical Research
Share
At Lampgen, we are a dedicated research partner for companies seeking to bring new medical therapies to market.
Lampgen Clinical Research was founded in 2012, a year in which 39 new molecular entities were approved by the FDA’s Center for Drug Evaluation and Research. At this time, over 120,000 studies had been registered on ClinicalTrial.gov, and this number was only increasing as innovation in biotechnology and bioinformatics yielded new potential therapies. With the volume of clinical studies rising, the need for qualified personnel to provide study oversight and experienced clinical sites was growing exponentially. While the volume of clinical trials were trending up during this period, according to the FDA Office of Scientific Investigations, the overall quality of several clinical investigations was not. Between 2009 and 2013, a total of 83 warning letters were issued by the FDA to clinical investigators, institution review boards (IRBs), biopharmaceutical companies, and CROs. Violations included findings such as improper supervision by clinical investigator, failure to obtain informed consent, and failure to properly monitor a clinical investigation. Issues such as these endanger the lives of clinical trials volunteers. Lampgen was founded to achieve a new standard in clinical development and aid companies in quality research. Lampgen’s model was developed from researching the best practices in clinical development at the academic, CRO, and Sponsor level. It was determined that providing companies with rapid access to expert clinical research professionals to provide oversight at sites was one key to quality clinical develoment. Additionally, it was ascertained that developing existing medical practices into viable research site with internal quality assurance was a proactive method of enhancing the integrity of a given trial. Combining these two elements, Lampgen came into existence with the goal of illuminating new pathways to clinical development.
01/17/2022
The Worst of the Omicron Wave Could Still Be Coming - The Atlantic http://ow.ly/T7jm30s7tjS
The Worst of the Omicron Wave Could Still Be Coming — The Atlantic A long descent from a peak in cases could exact a larger toll than even Omicron’s blistering ascent.
01/17/2022
Experts warn of more COVID-19 variants after Omicron - Axios http://ow.ly/Fznc30s7t9k
Experts warn of more COVID-19 variants after Omicron — Axios Experts are warning that subsequent COVID-19 variants are likely to come after Omicron, AP reports. Why it matters: The warnings come as there's no guarantee that subsequent variants "will cause milder illness or that existing vaccines will work against them," underscoring the need for widespread va...
01/17/2022
The COVID race to watch: vaccines vs. variants - The Wall Street Journal http://ow.ly/n3f930s7rJJ
The Covid Race to Watch: Vaccines vs. Variants — The Wall Street Journal Omicron won’t be the omega of Covid-19 variants. But global vaccination is the key to making sure the disease becomes endemic—and a lot more manageable.
01/17/2022
The Silent, Vaccinated, Impatient Majority - The Atlantic http://ow.ly/TMt030s7yzv
The Silent, Vaccinated, Impatient Majority — The Atlantic As patience with the pandemic wanes, leaders in widely vaccinated democracies are deploying a new political strategy.
01/10/2022
Why More Americans Are Saying They’re ‘Vaxxed and Done’ - The Atlantic http://ow.ly/FZoY30s6Pqr
Why More Americans Are Saying They’re ‘Vaxxed and Done’ — The Atlantic COVID has always divided Americans. The Omicron wave is even dividing the vaccinated.
01/10/2022
Recognizing obesity as a disease is a step toward health equity - STAT http://ow.ly/4fmZ30s6JyN
Recognizing obesity as a disease, not a choice, is a step toward health equity There is a palpable shift underway as government leaders and others are adopting a mindset about obesity that is informed by science rather than by prejudice.
01/05/2022
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine | BioNTech http://ow.ly/zk5x30s6gEm
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine | BioNTech Third mRNA vaccine collaboration between the companies aims to accelerate development of an improved vaccine for shingles, a debilitating, disfiguring and painful disease that affects people all over the world Product candidates will be based on BioNTech’s proprietary mRNA technology and on
01/05/2022
2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs | FiercePharma http://ow.ly/zBhU30s6egp
2021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugs Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 batch of new drug approvals clearly demonstrates that the sector has learned how to operate in a pandem...
01/05/2022
The Data Shows Omicron is Milder. How Should That Affect Your Behavior? - The New York Times http://ow.ly/Sso930s6gB9
Omicron is Milder How should that affect your behavior?
01/04/2022
Omicron Cases Are Hitting Highs, But New Data Puts End in Sight - Bloomberg http://ow.ly/n1PU30s65EM
Omicron Cases Are Hitting Highs, But New Data Put End in Sight — Bloomberg Data suggest hospitalizations are now decoupled from case numbers, and the variant causes less severe disease
01/04/2022
Opinion | Omicron Variant May End Up Saving Lives - The Wall Street Journal http://ow.ly/HNlr30s64Nj
Opinion | Omicron Variant May End Up Saving Lives — The Wall Street Journal It’s far less lethal than previous versions, and its fast spread may finally push us to herd immunity.
Click here to claim your Sponsored Listing.
Category
Contact the practice
Website
Address
4153 Flat Shoals Road
Decatur, GA
30034
Opening Hours
| Monday | 9am - 5pm |
| Tuesday | 9am - 5pm |
| Wednesday | 9am - 5pm |
| Thursday | 9am - 5pm |
| Friday | 9am - 5pm |